Effects of SGLT2 inhibitors on anemia in patients with diabetes and chronic kidney disease: A population-based cohort study using target trial emulation framework

被引：0
|
作者：
Hu, Jia-Chian [1 ]
Shao, Shih-Chieh [2 ]
Tsai, Daniel Hsiang-Te [1 ]
Chuang, Albert Tzu-Ming [1 ]
Liu, Kuan-Hung [3 ]
Lai, Edward Chia-Cheng [1 ]
机构：
[1] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
[2] Keelung Chang Gung Mem Hosp, Keelung, Taiwan
[3] Natl Cheng Kung Univ, Inst Clin Med, Coll Med, Tainan, Taiwan
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2023年 / 32卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
160
引用
收藏
页码：65 / 65
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    Scheen, Andre J.
    CLINICAL PHARMACOKINETICS, 2015, 54 (07) : 691 - 708
  • [32] The influence of SGLT2 inhibitors on oxidative stress in heart failure and chronic kidney disease in patients with type 2 diabetes
    Nabrdalik-Lesniak, Diana
    Nabrdalik, Katarzyna
    Irlik, Krzysztof
    Janota, Oliwia
    Kwiendacz, Hanna
    Szromek-Bialek, Paulina
    Maziarz, Miroslaw
    Stompor, Tomasz
    Gumprecht, Janusz
    Lip, Gregory Y. H.
    ENDOKRYNOLOGIA POLSKA, 2023, 74 (04) : 349 - 362
  • [33] Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease
    André J. Scheen
    Clinical Pharmacokinetics, 2015, 54 : 691 - 708
  • [34] Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease
    Cheng, Judy W. M.
    Colucci, Vincent
    Kalus, James S.
    Spinler, Sarah A.
    ANNALS OF PHARMACOTHERAPY, 2021, 55 (02) : 252 - 260
  • [35] SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study
    Schork, Anja
    Eberbach, Marie-Luise
    Bohnert, Bernhard N.
    Woern, Matthias
    Heister, David J.
    Eisinger, Felix
    Vogel, Elisabeth
    Heyne, Nils
    Birkenfeld, Andreas L.
    Artunc, Ferruh
    KIDNEY & BLOOD PRESSURE RESEARCH, 2024, 49 (01): : 124 - 134
  • [36] Adverse Effects Of Sglt2 Inhibitors In Older Patients With Congestive Heart Failure And The Influence Of Chronic Kidney Disease
    Mahmood, Riaz
    Robinson, Shane
    Kilaru, Vikas
    Amoran, Olayiwola
    Egolum, Ugochukwu
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01)
  • [37] Safety of SGLT2 inhibitors, DPP-4 inhibitors, and GLP-1 receptor agonists in US veterans with and without chronic kidney disease: a population-based study
    Narasaki, Yoko
    Kovesdy, Csaba P.
    You, Amy S.
    Sumida, Keiichi
    Mallisetty, Yamini
    Surbhi, Satya
    Thomas, Fridtjof
    Amin, Alpesh N.
    Streja, Elani
    Kalantar-Zadeh, Kamyar
    Rhee, Connie M.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 36
  • [38] Association of SGLT2 Inhibitors and Other Second Line Therapies With Incident Chronic Kidney Disease in Patients With Type 2 Diabetes
    Wang, Wendy
    Drawz, Paul
    Chow, Lisa
    Chen, Lin Y.
    Walker, Rob F.
    Norby, Faye L.
    Lutsey, Pamela L.
    CIRCULATION, 2024, 149
  • [39] The Uricosuric Effect of SGLT2 Inhibitors Is Maintained in the Long Term in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus
    Sanchez-Briales, Paula
    Vidas, Maria Marques
    Lopez-Sanchez, Paula
    Lopez-Illazquez, Maria Victoria
    Martin-Testillano, Lucia
    Vedat-Ali, Aylin
    Portoles, Jose
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [40] Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease
    Amioka, Michitaka
    Sanada, Ryuhei
    Matsumura, Hiroya
    Kinoshita, Hiroki
    Sairaku, Akinori
    Morishima, Nobuyuki
    Nakano, Yukiko
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2023, 370 : 294 - 299
12345